A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3682B (MK-3682/MK-5172/MK-8408 Fixed Dose Combination) When Administered to Subjects With Moderate and Severe Renal Insufficiency
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Grazoprevir/ruzasvir/uprifosbuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 29 Aug 2016 Status changed from active, no longer recruiting to completed.
- 02 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.
- 02 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Aug 2016.